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PN was 32 % in the BDD group versus 15 % in the BDD-A 
group (p = ns). Patient-reported fatigue and PN measured 
by FACT-GOG-TX increased throughout the treatment 
period in the BDD-A group, although time to complete 
GP testing declined. In a sub-study examining constitutive 
bortezomib-inducible NF-κB activity in primary subject-
specific MM cells, the presence of NF-κB activation cor-
related with lower likelihood of response.
Conclusions Addition of ALCAR to BDD did not alter 
the incidence or severity of PN in relapsed MM patients 
receiving a B-based regimen. Bortezomib-inducible NF-
κB activation in patient-derived primary MM cells may be 
associated with poorer response.
Keywords Multiple myeloma · Bortezomib · 
Neuropathy · Acetyl-l-carnitine · NF-kB
Introduction
Multiple myeloma is an incurable plasma cell malignancy 
with a course characterized by initial responsiveness to 
treatment, followed by the appearance of increasingly 
refractory disease and ultimately death due to infection, 
renal failure and cytopenias [1]. Until the last two decades, 
patients with MM had few therapeutic options after fail-
ing initial therapy with oral alkylators and steroids. Bort-
ezomib, the first clinically approved proteasome inhibitor 
proved to be a powerful new agent for the treatment of MM 
[2]. Initial trials of single agent bortezomib for relapsed 
MM resulted in response rates of 30–35 % [3, 4]. However, 
MM patients rapidly acquire resistance to bortezomib when 
used as a single agent, and it is apparent that this resist-
ance may in part be modified through combination with 
other existing chemotherapy agents, including steroids, 
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alkylating agents, anthracyclines and immunomodulatory 
drugs [5–7]. As more experience has been gained with 
these combinations, it is also apparent that some patients 
who have previously received bortezomib can be retreated 
at the time of relapse with excellent results [8]. However, 
predicting which relapsed patients will respond to retreat-
ment with bortezomib remains essentially a “trial and 
error” process.
An additional obstacle when considering retreatment 
of MM patients has been the rapid development of periph-
eral sensory and occasionally motor neuropathy that is 
the most frequently observed important non-hematologic 
toxicity of bortezomib. The exact mechanisms underlying 
bortezomib-induced PN remain unclear. Animal models 
of bortezomib-induced PN demonstrate damage to dorsal 
root ganglia (DRG) neuronal cell bodies including chro-
matolysis and accumulation of electron dense juxtanuclear 
cytoplasmic deposits [9]. Casafont et al. [10] demonstrated 
accumulation of poly (A) RNAs in nuclear granules and 
suggested that interference with pre-mRNA process-
ing may be a major pathologic event in the development 
of PN. The incidence and severity of peripheral neuropa-
thy (PN) is influenced by the schedule used (e.g., twice 
weekly versus weekly [11]), the route of administration 
(intravenous push versus subcutaneous [12]), and concur-
rent administration of other chemotherapeutic agents. In 
particular, combining bortezomib with anthracyclines pro-
duces some of the highest rates and severity of PN  [13, 
14]. The presence of certain genetic polymorphisms may 
also influence the incidence and severity of bortezomib-
related PN [15, 16].
In an effort to ameliorate peripheral neuropathy, some 
investigators have suggested the addition of various agents 
thought to be neuroprotective at the time PN emerges. For 
example Richardson et al. [17] in the initial phase II study 
of bortezomib for subjects with newly diagnosed myeloma, 
offered patients gabapentin as well as other supplements at 
the emergence of ≥grade 1 neuropathy. Anecdotal reports 
of improvement of PN have also been attributed to the use 
of a number of supplements, including alpha lipoic acid 
[18], and B vitamins including pyridoxine [19] and vitamin 
B12 [20].
Acetyl-l-carnitine (ALCAR), another compound of 
interest, is an ester of l-carnitine and a critical component 
in mitochondrial energetics and function. ALCAR appears 
to act as a transport molecule for fatty acids in and out of 
the axonal mitochondria, where they are then utilized in 
energy-producing metabolic cycles. In animal models of 
chemotherapy-induced PN, ALCAR, administered to rats 
dosed with paclitaxel, vincristine, oxaliplatin, or cispl-
atin, decreased the incidence of allodynia (the sensation 
of pain in response to a normal stimuli) [21–24]. It is not 
yet clear whether the benefits noted from ALCAR are due 
to the intact ester or to the combined effect of the acetyl 
and l-carnitine moieties formed by hydrolysis of the par-
ent molecule. Other attractive features of ALCAR are that 
it is extremely well tolerated, has no known drug interac-
tions, comes as an oral preparation and is available with-
out prescription as a dietary supplement. Studies in human 
subjects have suggested that ALCAR may be effective in 
treating patients with chemotherapy-induced NP in two 
uncontrolled, pilot trials [25, 26]. We therefore investi-
gated the ability of ALCAR to prevent the emergence of 
bortezomib-induced PN in a two part pilot study using the 
combination of bortezomib, doxorubicin and dexametha-
sone in a heavily pretreated group of patients. We spe-
cifically allowed enrollment of patients refractory to the 
bortezomib and dexamethasone doublet. In the first half 
of the study patients received the three-drug combination 
without ALCAR to examine the response rate and toxici-
ties. Although seemingly an active combination, we noted 
a high incidence of PN that affected the ability to deliver 
subsequent cycles of therapy. Therefore, patients accrued to 
the second part of the study received prophylactic ALCAR 
to see if the incidence and severity of PN would be reduced 
and to determine if response rates were maintained when 
ALCAR was included.
As an additional exploratory component of the study, 
we also sought to determine if we could predict an indi-
vidual subject’s response to the BDD combination by 
examining the inherent NF-κB activation status of the 
patient’s primary myeloma cells as this transcription factor 
activity has been implicated in promoting survival of can-
cer cells. The biological mechanisms underlying primary 
or acquired bortezomib resistance are not known although 
the development of structural variants in the β5-subunit of 
the 20S proteasome core has been cited [27]. Previously 
our group has demonstrated that a subset of primary MM 
cells isolated from patient bone marrow samples display 
enhanced constitutive NF-κB activity when exposed to 
bortezomib and such activation in MM cell lines corre-
lated with bortezomib-resistance in vitro [28]. We there-
fore sought to evaluate in a subset of patients receiving 
treatment on this trial whether we could correlate clini-
cal response with this phenomenon. We hypothesized that 
MM cells from responding subjects would be less likely to 
show bortezomib enhanced NF-κB activity and that non-
responders would display bortezomib-inducible NF-κB 
activity.
Methods
Patients with relapsed and/or refractory MM, including 
those relapsing on bortezomib, were eligible. Progressive/
relapsed disease was defined as an increase of >1 g/dl of 
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monoclonal protein, or >200 mg of protein in a 24-h urine 
collection; those subjects who progressed thusly while 
on or within 60 days of treatment were deemed refrac-
tory. Patients were informed of the investigational nature 
of the study and signed informed consent. The study was 
conducted at all Wisconsin Oncology Network sites after 
appropriate approval by individual institutional review 
boards in compliance with the Declaration of Helsinki 
and Good Clinical Practice Guidelines. Patients with pre-
existing >grade 2 peripheral motor or sensory neuropa-
thy were excluded. Minimum laboratory requirements 
included absolute neutrophils >1,500/mcl and platelets 
>100,000/mcl (unless the cytopenias were due to marrow 
replacement with MM), ALT and AST < 3 times the insti-
tutional upper limits, no more than 220 mg/m2 of previous 
doxorubicin exposure and left ventricular ejection fraction 
>40 % as determined by echocardiogram or MUGA within 
the previous 90 days. Prior to treatment, patients were 
staged with serum protein electrophoresis, 24-h urine col-
lection, skeletal survey and bone marrow biopsy.
Treatment consisted of bortezomib (B) 1.3 mg/m2 on 
day 1, 4, 8 and 11 intravenously, doxorubicin (D) 15 mg/m2 
on days 1 and 8 intravenously and dexamethasone (Dex) 
20 mg by mouth on days 1, 4, 8 and 11 for up to 8 cycles. 
Prophylactic acyclovir was required to prevent varicella 
reactivation. Dose reductions of B and D were used for 
cytopenias and treatment emergent PN. Growth factor use 
was allowed and encouraged per investigator discretion to 
maintain the dosing schedule.
As part of the neuroprotection portion of the trial, sub-
jects received the identical chemotherapy regimen but 
in addition received ALCAR 1.5 g by mouth twice daily. 
These patients answered the FACT-GOG-NTX and FACIT-
Fatigue [29] questionnaires at the time of enrollment, and 
prior to each odd cycle. A member of the research team 
administered the Grooved Peg Board test [30] in duplicate. 
Patients in either cohort achieving a complete remission 
(CR) underwent a bone marrow biopsy at that time to con-
firm response. CR was defined as no monoclonal protein 
detectable by immunofixation of serum and urine as well as 
<5 % plasma cells in the marrow. Partial response (PR) was 
defined as >50 % reduction in serum monoclonal protein, 
minimal response (MR) between 25 and 50 % reduction 
and progressive disease as at least 25 % increase in serum 
M protein (minimum >0.5 g/dl) or 200 mg in urine protein 
from the lowest level, new lytic bone lesions, or hypercal-
cemia. Responses were evaluated every two cycles.
Statistical analysis
Study outcomes were summarized in terms of means, 
standard deviations and ranges, or frequencies and per-
centages. Duration of response and overall survival were 
analyzed using the Kaplan–Meier method. GP, FACIT-
Fatigue, FACT/GOG-Neurotoxicity and NPI were analyzed 
using linear mixed effects models with subject-specific ran-
dom effects and paired t tests. An exact paired McNemar’s 
test was used to compare proportions between baseline and 
end of study assessments. All p values were two-tailed and 
p < 0.05 was used to define statistical significance. Data 
analysis was conducted using SAS software version 9.3 
(SAS Institute, Cary, NC).
NF-κB DNA-binding activity in primary MM cells
Bone marrow aspirate samples were collected from sub-
jects at the time of enrollment in the initial BDD cohort 
for the inducible NF-κB analysis. Eleven aspirate samples 
were evaluable. Eight other subjects could not be evalu-
ated either because a bone marrow sample was not sent 
for analysis by a study site or because the sample did not 
yield enough viable cells for analysis. CD138+ cells were 
sorted from aspirates and then were cultured with or with-
out 100 nM bortezomib (predetermined concentration 
required for >80 % proteasome inhibition). The cells were 
then lysed and NF-κB DNA-binding activity was evalu-
ated using the electrophoretic mobility shift assay (EMSA) 
adapted for small amounts of cellular protein [31]. The 
analysis of NF-κB DNA-binding activity was performed 
without knowledge of the patient’s response, and the data 
were only correlated with actual clinical data after all mar-
row samples had been analyzed.
Results of BDD/BDD-A treatment
A total of 19 patients were treated with BDD and 13 
patients received BDD plus ALCAR (BDD-A). Table 1 
displays characteristics of all subjects. The median age of 
the entire cohort was 64.5 years (range 39–88), and the 
median number of previous regimens was 5 (range 1–8). 
The median time from diagnosis to enrollment on the trial 
was a 29.1 months (range 5.4–108.1) for the entire cohort 
and was not statistically different between the BDD and 
BDD-A groups. Nineteen (59 %) patients were previously 
exposed to bortezomib. Twelve (38 %) of the patients were 
refractory to bortezomib, and 25 (78 %) were refractory 
to their most recent treatment. Fifteen (47 %) patients had 
undergone peripheral blood stem cell transplantation. Nine-
teen percent of patients had diabetes, 34 % had preexisting 
grade 1 neuropathy, related primarily to previous thalido-
mide or bortezomib exposure.
The percentage of patients with high-risk cytogenetic 
karyotype or FISH, defined as 13 deletion by cytogenetics, 
17p deletion, t(4:14), t (14:16) and t(14; 20) included 6/19 
(32 %) subjects in the BDD group and 6/13 subjects (46 %) 
in the BDD-A cohort and overall 38 % of subjects.
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Response to treatment
One patient in the BDD cohort was found to be ineligible 
due to preexisting LFT abnormalities, and four patients 
experienced progressive disease during the first two cycles 
of therapy. Response rates of the remaining subjects were 
53 % (95 % CI 36–69 %), with a CR + PR rate of 53 % 
(95 % CI 32–73 %) in the BDD cohort and 54 % (95 % 
CI 29–77 %) in the BDD-A cohort. If minimal response 
is included as an assessment of clinical benefit, these rates 
increased to 63 % (95 % CI 45–77 %) among all subjects, 
with 53 % (95 % CI 32–73 %) in the BDD and 77 % (95 % 
CI 50–92 %) in the ALCAR cohort (p = 0.35). These 
results compare favorably to previously reported results in 
relapsed/refractory patients receiving either bortezomib/
liposomal doxorubicin or PAD therapy. Not surprisingly, 
the response rates observed in high-risk patients were 
lower, 17 % in BDD and 33 % in BDD-A, respectively.
The median number of cycles of therapy delivered 
was 5 in both cohorts (range 1–8). The median dura-
tion of response was 3 months in the BDD cohort versus 
10 months in the BDD-A cohort (p = 0.097). Median over-
all survival rate calculated from time of enrollment for the 
group was 28.3 months (range 0.2–75.3+), with a median 
overall survival of 22.9 in the BDD cohort and 28.3 in 
BDD-A cohort (p = ns).
Toxicity
Patients in both cohorts experienced significant hemato-
logic toxicity as expected in this heavily pretreated cohort. 
No deaths were directly attributable to the treatment 
regimen. Forty-two percent (8/19) in the BDD and 46 % 
(6/13) in the BDD-A group developed >grade 3 hemato-
logic toxicity while on therapy, primary neutropenia and 
thrombocytopenia. Non-hematologic toxicity, mostly GI 
such as diarrhea, occurred in 41 % of the entire cohort. One 
subject in the BDD group developed a grade 4 infection 
with CMV (Table 2). 
Neurotoxicity
As assessed by the treating physician, six of 19 (32 %) 
receiving BDD developed grade 3/4 neuropathy, primarily 
sensory with one subject experiencing grade 4 neuropathy. 
However, in the ALCAR cohort, 2/13 (15 %) experienced 
grade ≥3 neurotoxicity, with no patients experiencing treat-
ment emergent grade 4 PN. This difference is not statisti-
cally different. Using a score of >0 on the FACT-GOG-
NTX scale on questions 1–4, 8 or 9, the baseline prevalence 
of any subjective neuropathy among the 13 patients in the 
BDD-A group cohort was 62 % (8/13). We also performed 
a statistical analysis of BDD-A subjects comparing results 
at the beginning and end of therapy on the Grooved Peg-
board (GP), the FACT-GOG-NTX, the FACIT-Fatigue and 
the NPI index (Table 3). Twelve (92 %) subjects reported 
significant fatigue prior to starting protocol-specified treat-
ment using a cutoff score of <30 on the FACIT-Fatigue 
Scale [29]. Only 2/13 reported an improvement in fatigue 
by the time they terminated the treatment (p = 0.98). The 
majority of patients reported an increase in both overall 
fatigue and symptoms such as numbness, allodynia and tin-
gling, as well as general discomfort in both the hands and 
feet over the course of the study as measured by the NPI 
Table 1  Patient demographics 
(n = 32) Mean (SD) Median Range
Age (years) 63.1 (11.7) 64.5 39–88
Number of previous treatments 4.9 (2.2) 5.0 1–8
Time from diagnosis to study entry (months) 37.1 (26.3) 29.1 5.4–108.1
N %
Gender
 Female 11 34
Ethnicity
 Non-hispanic 28 88
 Hispanic 3 9
 Unknown 1 3
Dose modifications while on study 12 37
Previous treatment with bortezomib 19 59
Refractory to previous treatment 25 78
Refractory to bortezomib 12 38
Lytic lesions 8 25
Diabetes 6 19
Preexisting neuropathy (≤grade 2) 11 34
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(Figs. 1, 2), although these increases were not statistically 
significant. 
NF-κB assessment: prediction of response to bortezomib
A total of 11 subjects in the BDD cohort had bone marrow 
samples available for testing of baseline NF-κB activation 
status in the presence of bortezomib. Plasma cells from 
seven subjects did not display significant inducible NF-
κB activation; of those, 5 (71 %) patients achieved a clini-
cal response (Fig. 2). In contrast to the 4 patients with 
bortezomib-inducible NF-κB activity, one (25 %) patient 
achieved stable disease, 2 patients experienced progres-
sive disease and one patient died during the first week of 
Table 2  Frequencies and percentages of treatment associated toxicities
BDD (N = 19) BDD-A (N = 13) BDD + BDD-A (N = 32)
Grade 3 Grade 4 Grade 3 Grade 4 Any grade
N (%) N (%) N (%) N (%) N (%)
ANC 1 (5) 3 (16) 2 (15) 2 (15) 15 (47)
Hemoglobin 1 (5) 1 (5) 1 (8) 0 (0) 8 (25)
Platelets 0 (7) 7 (37) 1 (8) 1 (8) 18 (56)
Infection 3 (2) 2 (11) 0 (0) 3 (23) 7 (22)
Lymphopenia 1 (5) 0 (0) 0 (0) 0 (0) 1 (3)
Nausea 1 (5) 0 (0) 0 (0) 0 (0) 7 (22)
Fatigue 1 (5) 0 (0) 0 (0) 0 (0) 10 (31)
Neuropathy 6 (32) 0 (0) 2 (15) 0 (0) 20 (62)
Pain 1 (5) 0 (0) 0 (0) 0 (0) 9 (28)
Diarrhea 2 (11) 1 (5) 2 (15) 0 (0) 14 (44)
Table 3  GP, FACIT-fatigue, FACT/GOG-neurotoxicity and NPI scores for BDD-A patients
* Statistically significant p < 0.05
a
 p value for evaluating changes from baseline to cycle 3
b
 p value for evaluating changes from baseline to end of treatment
Baseline (N = 13) Cycle 3 (N = 12) End of treatment (N = 10)
Mean (SD) Mean (SD) p valuea Mean (SD) p valueb
GP (Grooved Pegboard)
 Dominant (s) 99.5 (18.9) 103.7 (30.5) 0.443 103.0 (33.1) 0.711
 Non-dominant 94.1 (19.2) 101.2 (22.7) 0.221 94.1 (17.7) 0.326
 FACIT-fatigue 14.9 (11.0) 16.3 (7.7) 0.762 22.4 (11.2) 0.114
 FACT/GOG-neurotoxicity 5.9 (5.4) 8.9 (6.7) 0.113 10.9 (10.0) 0.101
NPI
 Intense 1.8 (2.7) 3.1 (3.2) 0.438 4.5 (3.4) 0.313
 Sharp 1.3 (2.4) 2.8 (3.2) 0.313 2.6 (3.4) 0.875
 Hot 0.3 (0.7) 1.4 (2.4) 0.375 3.3 (3.4) 0.125
 Dull 0.8 (1.5) 2.8 (3.6) 0.125 4.2 (3.0) 0.063
 Cold 0.0 (0.0) 0.9 (1.8) 0.500 2.3 (3.3) 0.250
 Sensitive 0.1 (0.9) 0.9 (1.5) 0.375 3.2 (3.1) 0.031*
 Itchy 0.0 (0.0) 0.3 (0.5) 0.500 1.6 (3.1) 0.250
Total 4.1 (6.3) 12.0 (14.4) 0.406 21.7 (14.2) 0.047*
N (%) N (%) p value N (%) p value
FACIT-fatigue < 30 12 (92) 11 (92) 0.999 8 (80) 0.980
FACIT-GOG NP > 0 8 (62) 9 (75) 0.480 6 (60) 0.999
880 Cancer Chemother Pharmacol (2014) 74:875–882
1 3
therapy due to disease. Although these patient numbers are 
small, this assay suggests that bortezomib-inducible activa-
tion of NF-κB may be an important marker of bortezomib 
resistance and could be used for treatment allocation.
Discussion
Bortezomib is an extremely active agent in relapsed MM 
patients, especially when combined with steroids and other 
compounds such as alkylating agents. In particular, numer-
ous reports attest to the utility of retreatment with bort-
ezomib. We have demonstrated that the combination of 
doxorubicin, low-dose dexamethasone and bortezomib is 
associated with a high response rate of 53 % (CR and PR), 
even in very refractory patients. This observed response 
rate is similar to that reported by Palumbo et al. [32] using 
a different dosing schedule of bortezomib, doxorubicin 
and dexamethasone. They found an overall response rate 
in 67 % of patients, although an important difference is 
that in their trial, greater than 60 % of patients received the 
three-drug bortezomib-based combination as their first- or 
second-line relapse therapy. However, both preexisting and 
Fig. 1  Mean and standard 
errors for GP, FACIT-Fatigue 
and FACT/GOG-Neurotoxicity 
scores at baseline, cycle 3 and 
end of study; a GP-dominant, b 
GP-non-dominant, c FACIT-
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Fig. 2  Electrophoretic mobility shift assay (EMSA) for NF-κB bind-
ing in RPMI8226 (“RPMI,” human multiple myeloma cell line) or 
primary CD138+ cells sorted from Pt. 10, 12 or 13 (as labeled). The 
NF-κB-specific band is designated “igκ” and the un-bound probe is 
labeled “Free probe”. Oct-1-DNA binding is used as a loading con-
trol. Lanes labeled “V” were treated with 100 nM bortezomib for 
4 h prior to harvest. Pt 10 and 13 showing bortezomib-inducible 
NF-κB activity did not respond to BDD treatment; pt 12, with 
no bortezomib-inducible Nf-κB activity, achieved a partial response 
(PR) to BDD
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treatment emergent neuropathy continues to be an impor-
tant consideration that limits long-term administration of 
bortezomib. We attempted to mitigate the incidence and 
severity of PN through the use of prophylactic acetyl-
l-carnitine. Our study suggests that the addition of ALCAR 
did not eliminate treatment-related PN, although there 
appeared to be fewer cases of grade 3 or 4 neuropathy 
among patients receiving the prophylaxis as reported by 
the treating physicians. However, as measured by validated 
instruments such as the FACIT-GOG-NTX and the NPI 
index, the subjects reported increasing levels of neuropathy 
and continuing fatigue as they continued on study. Given 
the observed continued high responses to the BDD-A com-
bination, it is clear that the inclusion of this agent in the 
treatment regimen did not diminish the response rate and 
ALCAR was very well tolerated. Major limitations of our 
study include the study’s small subject numbers and that 
we did not assess subjects receiving BDD with the same 
instruments, relying on PN assessment by study personnel 
using CTCAE criteria. Of note, in their BDD combination 
study, Palumbo reported only a 10 % incidence of grade 
3–4 treatment emergent PN, substantially lower than the 
25 % noted for our entire study. An important factor may 
be that the preexisting prevalence of PN in their subjects 
was 22 % compared to our subjects at 34 %.
Initial trials incorporating bortezomib quickly pointed to 
PN as an important toxicity of this drug [32, 33]. Other tri-
als incorporating bortezomib in previously treated patients 
have reported similar rates of PN and grade 3–4 toxicity. 
Orlowski et al. [34] in the pivotal trial of pegylated doxoru-
bicin and bortezomib reported an 80 % incidence of ≥grade 
3 adverse events (AE): 36 % of patients stopped therapy 
due to an AE. The incidence of PN was reported as 35 % 
with only 4 % reported as grade 3/4. Richardson et al. [16] 
published data from the SUMMIT and CREST trial of bort-
ezomib and dexamethasone in relapsed MM patients show-
ing that 80 % of subjects either reported PN or were clini-
cally assessed as having PN. In our much smaller study, we 
found that only 55 % of these heavily pretreated subjects 
reported significant PN but some of this difference may 
be due to the lower rate of exposure to thalidomide prior 
to enrollment (51 %) compared to subjects in those trials 
(72 %). Our observed rate of treatment emergent PN was 
also higher than that reported in either the SUMMIT [3] or 
CREST [4] trials. Newer methods of bortezomib dosing, 
such as subcutaneous or weekly administrations, appear to 
significantly lower the rate of PN, but it remains an impor-
tant issue [11, 12, 35]. These modifications would seem the 
current best approach in minimizing bortezomib-related 
PN as the preliminary data from our small study does not 
support any advantage for the inclusion of ALCAR in this 
clinical setting. ALCAR administered intramuscularly has 
been shown in a randomized double-blind trial to improve 
retroviral therapy-induced PN [36] and in a small series of 
patients on RT receiving long-term oral ALCAR [37]. It is 
therefore conceivable that the lack of protective effect in our 
trial may be due to different mechanisms of neuronal injury 
caused by bortezomib. It is also conceivable that the incor-
poration of ALCAR in bortezomib containing regimens 
earlier in the treatment course, e.g., for newly diagnosed 
MM patients, might offer a protective advantage against the 
development of PN. However, Hershman recently reported 
results from a large placebo-controlled, randomized trial 
in which breast cancer patients receiving adjuvant taxane-
based chemotherapy were assigned to ALCAR versus pla-
cebo. Their study found no improvement in patient-reported 
PN and actually showed an increase in PN severity in 
patients receiving ALCAR as measured by FACT-NTX and 
clinician assessment after 24 weeks of therapy [38]. Given 
the scope of this trial, it seems less likely that the reason we 
also did not observe a reduction in PN with the inclusion of 
ALCAR was due sample size.
We also examined the pretreatment activation status of 
NF-κB in primary myeloma cells obtained from bone mar-
row in a subset of patients. We found a correlation between 
clinically relevant bortezomib-resistance and bortezomib-
inducible NF-κB activation. Despite the use of what is 
considered an active regimen, there was a distinctly lower 
response rate among those patients whose primary mye-
loma cells displayed this characteristic. This bortezomib-
inducible activity was found both in subjects with previ-
ous exposure to B and in one B-naive subject who failed 
to respond to BDD. These interesting results raise the pos-
sibility of using such an assay at the time of staging bone 
marrow biopsy to help determine optimal therapy. How-
ever, the assay as conducted here requires large numbers 
of MM cells and we are attempting to modify the assay to 
allow for use of smaller aliquots of primary MM cells [39]. 
In the future, we hope this technology could be incorpo-
rated in real time to determine the most effective therapeu-
tic options for newly diagnosed and relapsed patients.
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